glp 1 agonists vs sglt2 inhibitors Common systemic effects of either or GLP-1R do not combine dpp-4 inhibitors

Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons

Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)

Contact us today for more information, or simply schedule an appointment online

& Witten, Z

By improving glycemic control, promoting weight loss, and potentially reducing cardiovascular risk, GLP-1 therapy may indirectly support cognitive health through optimization of metabolic and vascular parameters

GLP-1 medications begin working at the molecular level within hours, activating receptors in the brain and gut